Full data for Aimmune's peanut allergy therapy published in NEJM

The New England Journal of Medicine published full data from the Phase III PALISADE trial of peanut allergy therapy AR101 from Aimmune Therapeutics Inc. (NASDAQ:AIMT), including detailed safety showing a higher rate of rescue epinephrine use in the active arm vs. placebo arm.

In February, Aimmune reported that AR101 met PALISADE's primary endpoint of a greater proportion of patients ages 4-17 who were able to tolerate a dose of at least 600 mg of peanut protein -- at least two peanuts according to Aimmune -- at the exit food challenge vs. placebo (67.2% vs. 4%, p<0.00001). Patients in the primary analysis group tolerated no more than 30 mg of peanut protein at baseline (see "Aimmune's Peanut Allergy Therapy Meets in Phase III")...